Alexandria Real Estate Equities, Inc. (NYSE: ARE), an S&P 500 company, is a best-in-class, mission-driven life science REIT making a positive and lasting impact on the world. As the pioneer of the life science real estate niche with our founding in 1994, Alexandria is the preeminent and longest-tenured owner, operator, and developer of collaborative mega campuses in AAA life science innovation cluster locations, including Greater Boston, the San Francisco Bay Area, San Diego, Seattle, Maryland, Research Triangle, and New York City. As of September 30, 2024, Alexandria has a total market capitalization of $33.1 billion and an asset base in North America that includes 41.8 million RSF of operating properties, 5.3 million RSF of Class A/A+ properties undergoing construction, and one committed near-term project expected to commence construction in the next two years. Alexandria has a longstanding and proven track record of developing Class A/A+ properties clustered in mega campuses that provide our innovative tenants with highly dynamic and collaborative environments that enhance their ability to successfully recruit and retain world-class talent and inspire productivity, efficiency, creativity, and success. Alexandria also provides strategic capital to transformative life science companies through our venture capital platform. We believe our unique business model and diligent underwriting ensure a high-quality and diverse tenant base that results in higher occupancy levels, longer lease terms, higher rental income, higher returns, and greater long-term asset value.

Alexandria Real Estate Equities Inc.

Mare Engineering Group SpA ( ($IT:MARE) ) just unveiled an update. Mare Group S.p.A. has received the ‘Golden Power’ authorization from the Italian...

Mare Group Secures ‘Golden Power’ Approval for Eles Acquisition

Cantor Fitzgerald analyst Kristen Kluska maintained a Buy rating on Ultragenyx Pharmaceutical yesterday and set a price target of $105.00. The comp...

Cantor Fitzgerald Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

There’s a lot to be optimistic about in the Materials sector as 2 analysts just weighed in on American Resources (AREC – Research Report) and Boise...

Analysts Are Bullish on These Materials Stocks: American Resources (AREC), Boise Cascade (BCC)

Tactical Resources Corp. ( ($TSE:RARE) ) just unveiled an update. Tactical Resources Corp. announced that it has mailed meeting materials to its sh...

Tactical Resources Corp. Proposes Business Combination to Form New Entity

An update from Various Eateries PLC ADR ( ($GB:VARE) ) is now available. Various Eateries PLC has issued 1,000,000 options over ordinary shares to ...

Various Eateries PLC Issues Share Options to New Managing Director

American Resources Corp ( ($AREC) ) has released its Q3 earnings. Here is a breakdown of the information American Resources Corp presented to its i...

American Resources Corp Reports Q3 2025 Earnings

The Arena Group Holdings Inc. (($AREN)) has held its Q3 earnings call. Read on for the main highlights of the call. The Arena Group Holdings Inc. r...

The Arena Group’s Earnings Call Highlights Resilience and Growth

Artis Reit (OTC) ( ($ARESF) ) has released its Q3 earnings. Here is a breakdown of the information Artis Reit (OTC) presented to its investors. Art...

Artis REIT Reports Q3 Results and Strategic Merger

Mare Engineering Group SpA ( ($IT:MARE) ) has issued an announcement. Mare Engineering Group SpA has received a credit rating upgrade from modefina...

Mare Engineering Group SpA Receives Credit Rating Upgrade

Carter Bankshares ( ($CARE) ) just unveiled an update. On November 13, 2025, Carter Bankshares, Inc. announced that its subsidiary, Carter Bank, re...

Carter Bankshares Subsidiary Gains State Member Bank Approval

An update from Tactical Resources Corp. ( ($TSE:RARE) ) is now available. Tactical Resources Corp has secured a US$140 million financing package fr...

Tactical Resources Secures $140M Financing to Boost US Rare Earth Supply

In a report released yesterday, Douglas Tsao from H.C. Wainwright maintained a Buy rating on Daré Bioscience, with a price target of $12.00. Tsao c...

Daré Bioscience (DARE) Gets a Buy from H.C. Wainwright

In a report released on November 3, Farrell Granath from Bank of America Securities reiterated a Hold rating on Alexandria Equities, with a price t...

Bank of America Securities Reaffirms Their Hold Rating on Alexandria Equities (ARE)

In a report released today, Luca Issi from RBC Capital maintained a Buy rating on Ultragenyx Pharmaceutical, with a price target of $72.00. Issi co...

RBC Capital Reaffirms Their Buy Rating on Ultragenyx Pharmaceutical (RARE)

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Ultragenyx Pharmaceutical, with a price target of $75.00. The com...

TD Cowen Sticks to Their Buy Rating for Ultragenyx Pharmaceutical (RARE)

Mare Engineering Group SpA ( ($IT:MARE) ) just unveiled an update. Mare Group S.p.A. has announced an update to its 2025 Corporate Events Calendar,...

Mare Group Updates 2025 Corporate Events Calendar with Key Financial Review

Carter Bankshares ( ($CARE) ) just unveiled an announcement. Carter Bankshares, Inc. released an investor presentation detailing its financial perf...

Carter Bankshares Reports Q3 2025 Financial Performance

The latest announcement is out from Mare Engineering Group SpA ( ($IT:MARE) ). Mare Group S.p.A. has received approval from the Presidency of the C...

Mare Group Receives Approval for Powerflex Merger

In a report released today, Benjamin Budish from Barclays maintained a Buy rating on Ares Management, with a price target of $187.00. The company’s...

Ares Management (ARES) Gets a Buy from Barclays

There’s a lot to be optimistic about in the Materials sector as 2 analysts just weighed in on Coeur Mining (CDE – Research Report) and American Res...

Analysts’ Top Materials Picks: Coeur Mining (CDE), American Resources (AREC)

Ares Management Lp ( ($ARES) ) has released its Q3 earnings. Here is a breakdown of the information Ares Management Lp presented to its investors. ...

Ares Management Reports Strong Q3 2025 Results

William Blair analyst Neal Dingmann maintained a Buy rating on American Resources today. The company’s shares closed today at $4.00. Dingmann cover...

American Resources (AREC) Gets a Buy from William Blair

RBC Capital analyst Ashish Sabadra maintained a Hold rating on Aecon Group Inc. today and set a price target of C$30.00. The company’s shares opene...

Aecon Group Inc. (ARE) Receives a Hold from RBC Capital

The latest announcement is out from Aecon Group Inc. ( ($TSE:ARE) ). Aecon Group Inc.’s subsidiary, Aecon Utilities, has agreed to acquire KPC, a c...

Aecon Utilities to Acquire KPC, Enhancing Infrastructure Capabilities

Aecon Group Inc. (($TSE:ARE)) has held its Q3 earnings call. Read on for the main highlights of the call. Aecon Group Inc.’s latest earnings call p...

Aecon Group Inc. Reports Record Revenue Amid Challenges

Mare Engineering Group SpA ( ($IT:MARE) ) has provided an announcement. Mare Engineering Group S.p.A. has announced the acquisition of 2,607,445 wa...

Mare Group Acquires Significant Stake in Eles Semiconductor Warrants

Market volatility increased during the month. 


AMD, JBHT, FI: October’s Best and Worst-Performing Stocks

In a report released today, Michael Tupholme from TD Cowen maintained a Buy rating on Aecon Group Inc., with a price target of C$39.00. The company...

TD Cowen Keeps Their Buy Rating on Aecon Group Inc. (ARE)

RBC Capital analyst Sabahat Khan maintained a Hold rating on Aecon Group Inc. on October 29 and set a price target of C$26.00. The company’s shares...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Ultragenyx Pharmaceutical (RARE – Research Report) a...

Analysts Offer Insights on Healthcare Companies: Ultragenyx Pharmaceutical (RARE) and Exelixis (EXEL)

Ultragenyx Pharmaceutical ( ($RARE) ) just unveiled an update. On October 30, 2025, Ultragenyx Pharmaceutical announced the dosing of the first pat...

Ultragenyx Begins Dosing in Aurora Study for Angelman Syndrome

The SPDR S&P 500 ETF Trust ($SPY) gained 0.05% on Wednesday, fueled by optimism over artificial intelligence (AI) stocks, especially Nvidia ($NVDA)...

SPY ETF Daily Update, 10/29/2025

The latest announcement is out from Mare Engineering Group SpA ( ($IT:MARE) ). Mare Group S.p.A. announced the final results of its voluntary publi...

Mare Group Acquires Significant Stake in Eles Warrants

Ultragenyx Pharmaceutical, Inc. (($RARE)) announced an update on their ongoing clinical study. Ultragenyx Pharmaceutical Inc. is conducting a follo...

Ultragenyx’s Ongoing Study on UX111: A Potential Game-Changer for MPS IIIA Treatment

Ultragenyx Pharmaceutical, Inc. (($RARE)) announced an update on their ongoing clinical study. Study Overview: Ultragenyx Pharmaceutical Inc. is co...

Ultragenyx’s LC-FAOD Study: A Strategic Move in Rare Disease Management

Raymond James analyst Steve Moss reiterated a Buy rating on Carter Bankshares today and set a price target of $22.00. The company’s shares closed l...

Raymond James Reaffirms Their Buy Rating on Carter Bankshares (CARE)

Mare Engineering Group SpA ( ($IT:MARE) ) just unveiled an announcement. Mare Group S.p.A. has announced its participation in the second week of th...

Mare Group Extends Offer Period for Eles Warrants Acquisition

An announcement from Mare Engineering Group SpA ( ($IT:MARE) ) is now available. Mare Group S.p.A., an engineering firm listed on Euronext Growth M...

Mare Group Updates Warrant Offer for Eles Semiconductor

The latest announcement is out from Mare Engineering Group SpA ( ($IT:MARE) ). Mare Group has increased its offer for Eles Semiconductor Equipment ...

Market Cap	$9.61B	P/E Ratio	5.66
52W High	$112.42	52W Low	$48.66
Div Yield	528.0%	Payout Ratio	-82.7%
EPS Growth 3Y	-22.3%	52W Position	3.5%
Overall Score	42	Value Score	60
Quality Score	--	Technical Score	25

EPS Current Est	$8.99	EPS Next Est	$7.37
EPS Growth Est	-18.0%	DPS Growth 3Y	0.0%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	ARE	$50.89	+4.15%	2.79M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	ARE	$50.89	+4.2%	2.79M
3
4
5
6

ARE

ARE

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Alexandria Real Estate Equities Inc. Data in Excel

Get Alexandria Real Estate Equities Inc. Data in Excel